arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Xeris Biopharma Holdings, Inc.

XERS

$13.10 ▲ +2.63 (+25.19%) at close

7 Visible periods

31 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Bearish

auto_awesome

Analytical Summary

Xeris Biopharma Holdings, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $2.1B

Dividend Yield —

Revenue Growth 43.7% ↗

Op. Margin 8.5% ↗

ROIC 10.6% ↗

FCF / Share $0.18 ↗

Trailing P/E —

Price / Book 159.1x

FCF Yield 1.4%

Debt / Equity 16.10

info Valuation on last close. End-of-day price, Nov 5, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$291.85M

↑ +43.7% —

Net Income Profit after all expenses

$554.00K

↑ +101.0% —

Operating Margin Operating profit as % of sales

8.5%

↑ +151.5% 53th

FCF / Share Free cash flow per share

$0.18

↑ +170.8% —

Long-Term Debt Long-term obligations

$220.34M

↓ -5.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability

Returns

Financial Health ↑

Cash Quality ↑

100

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	43.7% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+446%)	23.9% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+199%)	48.7% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+508%)	122.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1429%)	142.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1683%)	—	—
EPS Growth YoY (%)	100.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	17.8% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	35.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	54.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	N/M	11.9% Fair ↑ Fair Improving Year-over-year change in net income	34.2% Excellent ↑ Excellent Improving Year-over-year change in net income	22.9% Good Good Year-over-year change in net income	-34.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	N/M	26.2% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	55.0% Excellent Excellent Year-over-year change in free cash flow	37.2% Excellent Excellent Year-over-year change in free cash flow	—	—	—
Revenue CAGR 3Y (%)	38.3% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	60.0% Excellent Excellent Compound annual revenue growth over 3 years	100.2% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	70.2% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	8.5% Caution ↑ Caution Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-43%)	-16.6% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-210%)	-26.8% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-279%)	-74.3% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-595%)	-232.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1648%)	-408.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2826%)	—
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	4.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	2.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
Profit Margin (%) (%)	0.2% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-98%)	-27.0% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-325%)	-38.0% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-417%)	-85.9% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-816%)	-247.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2162%)	-446.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3817%)	—
FCF Margin (%) (%)	9.8% Caution ↑ Caution Improving Free cash flow as a percentage of revenue Optimal: > 10%	-18.2% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-28.7% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-93.3% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-192.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-396.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	51.67x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.09x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	10.6% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	-16.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-23.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-34.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-49.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-54.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	6.5% Caution ↑ Caution Improving Operating profit relative to total assets Optimal: > 10%	-10.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-13.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-23.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-37.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-52.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	4.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-73%)	185.2% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1134%)	—	-209.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1497%)	-128.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-959%)	-270.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1900%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	16.10x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+2583%)	-7.84x Excellent → Excellent Stable Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-1406%)	-28.15x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-4792%)	4.14x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+590%)	0.92x Fair Fair Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+54%)	2.58x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+330%)	—
Interest Coverage (x)	0.92x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1.25x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1.59x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-5.81x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-16.04x Weak Weak Operating income divided by interest expense Optimal: > 5x	-7.84x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$109.29M	$160.49M	$123.48M	$65.11M	$20.80M	$49.42M	$-19.52M
Debt / EBITDA (x)	8.41x Weak ↑ Weak Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-7.16x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-4.49x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-2.32x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.77x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.06x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$1.82	$1.38	$1.19	$0.81	$0.63	—	—
Basic EPS, GAAP (USD)	$0.00	$-0.37	$-0.45	$-0.70	$-1.55	—	—
Free Cash Flow per Share (USD)	$0.18	$-0.25	$-0.34	$-0.76	$-1.21	—	—
Book Value per Share (USD)	$0.08	$-0.20	$-0.05	$0.33	$0.76	—	—
Tangible Book Value per Share (USD)	$-0.59	$-1.01	$-1.01	$-0.72	$-0.47	—	—
Basic Weighted Avg Shares (shares)	160.43M	146.77M	137.67M	135.63M	79.03M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$130.74M	$67.22M	$61.07M	$113.20M	$63.56M	$124.00M	—
LT Debt (USD)	$220.34M	$232.11M	$190.93M	$187.07M	$88.07M	$87.02M	—
Total Equity (USD)	$13.69M	$-29.61M	$-6.78M	$45.19M	$95.23M	$33.76M	$14.44M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$291.85M	$203.07M	$163.91M	$110.25M	$49.59M	$20.43M	—
Depreciation Expense (USD)	$1.31M	$1.23M	$1.49M	$1.40M	$1.33M	$1.47M	—
Net Income, GAAP (USD)	$554.00K	$-54.84M	$-62.26M	$-94.66M	$-122.72M	$-91.14M	—
Operating Cash Flow (USD)	$28.63M	$-36.98M	$-47.02M	$-102.89M	$-95.53M	$-80.56M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters

Xeris Biopharma Holdings, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare XERS with peers